New RNA aptamers specific for lipopolysaccharide-binding protein, useful for diagnosis and treatment of sepsis, inhibit the lipopolysaccharide-induced signaling cascade

/Home/Lyophilization and Protein Formulation Patents/Patents - Biologics/European Patents - Biologics

New RNA aptamers specific for lipopolysaccharide-binding protein, useful for diagnosis and treatment of sepsis, inhibit the lipopolysaccharide-induced signaling cascade
Inventor: ALDAG JASMIN (DE); HARTMANN ROLAND (DE)
Applicant: TRANSMIT GES FUER TECHNOLOGIET (DE)
EC: A61K31/713; A61K31/7088
IPC: A61K31/7088; A61K31/7115; A61K31/713
Publication info: DE102004002351
Date: 2005-08-11
Abstract of DE102004002351
RNA aptamers (I), or their alleles and/or derivatives, that bind specifically to lipopolysaccharide-binding protein (LBP) are new. - An INDEPENDENT CLAIM is also included for a method for preparing and/or isolating (I). - ACTIVITY - Antibacterial; Immunosuppressive. No details of tests for these activities are given. - MECHANISM OF ACTION - Inhibition of LBP, a key component in the lipopolysaccharide-induced signaling cascade.